FRONTotemporal dementia Incidence European Research Study—FRONTIERS: Rationale and design

FRONTIERS

Research output: Contribution to journalReview articleAcademicpeer-review

12 Citations (Scopus)
18 Downloads (Pure)

Abstract

Introduction: The incidence of Frontotemporal Lobar Degeneration (FTLD)–related disorders and their characteristics are not well known. The “FRONTotemporal dementia Incidence European Research Study” (FRONTIERS) is designed to fill this gap. Methods: FRONTIERS is a European prospective, observational population study based on multinational registries. FRONTIERS comprises 11 tertiary referral centers across Europe with long-lasting experience in FTLD-related disorders and comprehensive regional referral networks, enabling incidence estimation over well-defined geographical areas. Endpoints: The primary endpoints are (1) the incidence of FTLD-related disorders across Europe; (2) geographic trends of FTLD-related disorders; (3) the distribution of FTLD phenotypes in different populations and ethnicities in Europe; (4) inheritance of FTLD-related disorders, including the frequencies of monogenic FTLD as compared to overall disease burden; and (5) implementation of data banking for clinical and biological material. Expected impacts: FRONTIERS will improve the understanding of FTLD-related disorders and their epidemiology, promoting appropriate public health service policies and treatment strategies.

Original languageEnglish
Pages (from-to)498-506
Number of pages9
JournalAlzheimer's and Dementia
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2022

Bibliographical note

Funding Information:
Frontiers has been partially granted for the first meeting held in Tricase, Italy by the following: Biogen, Cambridge, MA, USA; Alector, South San Francisco, California, USA; and Tecnopolo Puglia per la Medicina di Precisione D.G.R. Regione Puglia n. 2117 of 21.11.2018. Barbara Borroni received honoraria from Alector and Wave Pharmaceuticals; she reported a patent pending on Non Invasive Brain Stimulation method. Caroline Graff received funds from Schörling Foundation, Swedish FTD Initiative, Swedish Dementia Foundation, Swedish Research Council, Swedish Brain Foundation, and Stohnes Foundation Gamla Tjänarinnor; and she received travel funds for participation in a congress as speaker. Orla Hardiman received funds from Science Foundation Ireland Health Research Board, MND Association UK ALSA, and TRICALS Research Motor Neuron; and she received personal fees from Biogen Idec, Cytokinetics Orion, Wave Pharmaceuticals, Biogen, and Novartis. Albert C. Ludolph received funds from State of Baden-Württemberg. Fermin Moreno received funds from Tau Consortium (Grant, Institution) and Instituto de Salud Carlos III (Grant, Institution). Markus Otto received funds from the German Ministry of Science and Technology, EU, Thierry Latran foundation, and FTLD CSF society; he received personal fees from Roche and Axon. Marco Piccininni received funds from Novartis Pharma for a self-initiated research project, unrelated to this work, on migraine remission. He was awarded with a research grant from the Center for Stroke Research Berlin (private donations) for a self-initiated project, unrelated to this work, on causal diagrams. He worked as a consultant for SANITANOVA S.r.l. in 2018; he received travel funds from Department of Clinical Research in Neurology, University of Bari “Aldo Moro” at Pia Fondazione Card. G. Panico and Institution Charité—Universitätsmedizin Berlin. Anne M Remes received funds from Academy of Finland, no. 315460, AMR. James B Rowe received funds from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014), Medical Research Council (SUAG/051 G101400), Welcome Trust, Evelyn Trust, Alzheimer's Research UK, PSP Association, Cambridge Centre for Parkinson-plus; he had a pro bono relationship with Guarantors of Brain, Trustee PSP Association, Trustee, Darwin College; he received personal fees from Asceneuron, UCB, Wave Pharmaceuticals, Biogen, Astex, SV Health, GE Healthcare, Copenhagen University. Harro Seelaar received funds from the ZonMW (project 733050513). Elka Stefanova received funds from the Alzheimer's Association; she received personal fees from Actavis Teva Pharma Swiss KRKA, Actavis Teva Krka. Latchezar Traykov has nothing to disclose. Giancarlo Logroscino received funds from Roche, Amplifon; he received travel funds for participation in a congress as speaker.

Publisher Copyright:
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Fingerprint

Dive into the research topics of 'FRONTotemporal dementia Incidence European Research Study—FRONTIERS: Rationale and design'. Together they form a unique fingerprint.

Cite this